2024-10-29 I-Mab Biopharma HaiPress
ROCKVILLE,Md.,Oct. 28,2024 --I-Mab (NASDAQ: IMAB),a US-based,global,biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer,today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7,2024.
Event Details
Meeting Date
Thursday,November 7,2024
Meetings
One-on-one and small group meetings:November 7,2024
Management
Participants
Sean Fu,PhD,MBA,Interim Chief Executive Officer (CEO)
Joe Skelton,Chief Financial Officer (CFO)
Phillip Dennis,MD,Chief Medical Officer (CMO)
Tyler Ehler,Senior Director,Investor Relations
For more information,please contact your Truist Securities representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based,global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville,Maryland,and Short Hills,New Jersey.For more information,please visithttps://www.i-mabbiopharma.comand followus onLinkedIn andX.
For more information,please contact:
Tyler Ehler
Senior Director,Investor Relations
IR@imabbio.com
Federal Reserve Data Released: Industrial Output Continues to Decline
State Grid Bortala Power Supply Company: Achieving the Application of Feeder Automation
China Matters' Feature: Beidahuang: Green Development on Black Soil
Hong Kong Screen Legend Chow Yun Fat Hosts Charity Photography Exhibition "Hong Kong‧Morning" at Harbour City, Showcasing 30 Stunning City Photographs
GEEKOM's high-performance mini PCs will shine at CES2025
Potech Group Expands Global Presence with New Entity Launch in Australia
©copyright 2009-2020 Singapore Info Map